

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/033334-2022>

Tender

(NU/1824) The Provision of Clinical Research Support & Central Laboratory Services for the ADVANCE Study

Newcastle University

F02: Contract notice

Notice identifier: 2022/S 000-033334

Procurement identifier (OCID): ocids-h6vhtk-0387f3

Published 24 November 2022, 10:36am

Section I: Contracting authority

I.1) Name and addresses

Newcastle University

Newcastle University, Procurement Services, Kingsgate

Newcastle

NE1 7RU

Contact

Dr Emma Barksby

Email

emma.barksby@ncl.ac.uk

Telephone

+44 1912086298

Country

United Kingdom

Region code

UKC22 - Tyneside

Internet address(es)

Main address

<https://www.ncl.ac.uk>

Buyer's address

<https://www.ncl.ac.uk>

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at

<https://procontract.due-north.com/>

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

<https://procontract.due-north.com/>

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Education

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

(NU/1824) The Provision of Clinical Research Support & Central Laboratory Services for the ADVANCE Study

Reference number

DN644540

II.1.2) Main CPV code

- 73110000 - Research services

II.1.3) Type of contract

Services

II.1.4) Short description

The Newcastle University Translational and Clinical Research Institute is one of three research institutes established in 2019 following a restructure within the Faculty of Medical Sciences. Its members map across the biomedical research landscape. A number of major research projects are led from within the Institute including the “NASH Disease Translational Accelerator” (NASH-DTA) project. This project funded brings together clinicians and scientists from prominent academic centres across Europe and industrial partners to conduct research into advanced liver disease/cirrhosis caused by non-alcoholic fatty liver disease (NAFLD). Their common goals are developing, validating and qualifying better biomarkers for NAFLD. Strongly associated with the epidemics of obesity and type 2 diabetes that are testing healthcare systems worldwide, NAFLD is an increasingly common cause of advanced liver disease that is characterized by substantial inter-patient variability in severity and rate of progression. Biomarkers under investigation in the project include genes that contribute to NAFLD progression.

The purpose of this tender process is to engage a supplier to provide clinical research support, central laboratory services and to oversee biological sample transfers and provide centralised laboratory processing of biological samples collected during the course of the study.

II.1.5) Estimated total value

Value excluding VAT: £2,200,000

II.1.6) Information about lots

This contract is divided into lots: No

II.2) Description

II.2.2) Additional CPV code(s)

- 73111000 - Research laboratory services

II.2.3) Place of performance

NUTS codes

- UKC22 - Tyneside

II.2.4) Description of the procurement

The Newcastle University Translational and Clinical Research Institute is one of three research institutes established in 2019 following a restructure within the Faculty of Medical Sciences. Its members map across the biomedical research landscape. A number of major research projects are led from within the Institute including the “NASH Disease Translational Accelerator” (NASH-DTA) project. This project funded brings together clinicians and scientists from prominent academic centres across Europe and industrial partners to conduct research into advanced liver disease/cirrhosis caused by non-alcoholic fatty liver disease (NAFLD). Their common goals are developing, validating and qualifying better biomarkers for NAFLD. Strongly associated with the epidemics of obesity and type 2 diabetes that are testing healthcare systems worldwide, NAFLD is an increasingly common cause of advanced liver disease that is characterized by substantial inter-patient variability in severity and rate of progression. Biomarkers under investigation in the project include genes that contribute to NAFLD progression.

The purpose of this tender process is to engage a supplier to provide clinical research support, central laboratory services and to oversee biological sample transfers and provide centralised laboratory processing of biological samples collected during the course of the study.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £2,200,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

60

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.3) Information about a framework agreement or a dynamic purchasing system

The procurement involves the establishment of a framework agreement

Framework agreement with a single operator

In the case of framework agreements, provide justification for any duration exceeding 4 years:

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: No

IV.2) Administrative information

IV.2.2) Time limit for receipt of tenders or requests to participate

Date

5 January 2023

Local time

12:00pm

IV.2.4) Languages in which tenders or requests to participate may be submitted

English

IV.2.7) Conditions for opening of tenders

Date

5 January 2023

Local time

2:00pm

Section VI. Complementary information

VI.1) Information about recurrence

This is a recurrent procurement: No

VI.4) Procedures for review

VI.4.1) Review body

Newcastle University

Newcastle upon Tyne

Country

United Kingdom

VI.4.3) Review procedure

Precise information on deadline(s) for review procedures

Newcastle University will incorporate a minimum 10 calendar day standstill period at the point information on the award of the contract is communicated to tenderers. This period allows unsuccessful tenderers to seek further debriefing before the contract is entered into. Applicants have 2 working days from notification of the award decision to request additional debriefing and 4 / 4 that information has to be provided a minimum of 3 working days before expiry of the standstill period. Such additional information should be requested from the address referred to in part 1.1 above. If an appeal regarding the award of a contract has not been successfully resolved, the Public Contracts Regulations 2015 provide for aggrieved parties who have been harmed or are at risk of harm by a breach of the rules to take action in the High Court (England, Wales and Northern Ireland). Any such action must be brought promptly. Where a contract has not been entered into the Court may order the setting aside of the award decision or order the authority to amend any document and may award damages. If the contract has been entered into the Court may only award damages